KR20100099352A - 건선 치료용 약제 제조를 위한 벌사상자 열매의 전체 쿠마린의 용도 - Google Patents
건선 치료용 약제 제조를 위한 벌사상자 열매의 전체 쿠마린의 용도 Download PDFInfo
- Publication number
- KR20100099352A KR20100099352A KR1020107018912A KR20107018912A KR20100099352A KR 20100099352 A KR20100099352 A KR 20100099352A KR 1020107018912 A KR1020107018912 A KR 1020107018912A KR 20107018912 A KR20107018912 A KR 20107018912A KR 20100099352 A KR20100099352 A KR 20100099352A
- Authority
- KR
- South Korea
- Prior art keywords
- coumarin
- psoriasis
- present
- ointment
- rat
- Prior art date
Links
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 title claims abstract description 126
- 235000001671 coumarin Nutrition 0.000 title claims abstract description 68
- 201000004681 Psoriasis Diseases 0.000 title claims abstract description 22
- 239000003814 drug Substances 0.000 title claims abstract description 21
- 235000013399 edible fruits Nutrition 0.000 title claims description 23
- 150000004775 coumarins Chemical class 0.000 title description 8
- 241000212948 Cnidium Species 0.000 title description 3
- 229960000956 coumarin Drugs 0.000 claims abstract description 61
- 239000002674 ointment Substances 0.000 claims description 47
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
- 239000000284 extract Substances 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 5
- BGEBZHIAGXMEMV-UHFFFAOYSA-N 5-methoxypsoralen Chemical compound O1C(=O)C=CC2=C1C=C1OC=CC1=C2OC BGEBZHIAGXMEMV-UHFFFAOYSA-N 0.000 claims description 4
- QXKHYNVANLEOEG-UHFFFAOYSA-N Methoxsalen Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 claims description 3
- PCWZKQSKUXXDDJ-UHFFFAOYSA-N Xanthotoxin Natural products COCc1c2OC(=O)C=Cc2cc3ccoc13 PCWZKQSKUXXDDJ-UHFFFAOYSA-N 0.000 claims description 3
- -1 coumarin compound Chemical class 0.000 claims description 3
- 229960004469 methoxsalen Drugs 0.000 claims description 3
- SQBBOVROCFXYBN-UHFFFAOYSA-N methoxypsoralen Natural products C1=C2OC(=O)C(OC)=CC2=CC2=C1OC=C2 SQBBOVROCFXYBN-UHFFFAOYSA-N 0.000 claims description 3
- DBMJZOMNXBSRED-UHFFFAOYSA-N Bergamottin Natural products O1C(=O)C=CC2=C1C=C1OC=CC1=C2OCC=C(C)CCC=C(C)C DBMJZOMNXBSRED-UHFFFAOYSA-N 0.000 claims description 2
- GIJHDGJRTUSBJR-UHFFFAOYSA-N Bergaptol Natural products O1C(=O)C=CC2=C1C=C1OC=CC1=C2O GIJHDGJRTUSBJR-UHFFFAOYSA-N 0.000 claims description 2
- RNKZFOIQKCQOAQ-UHFFFAOYSA-N Isopimpinellin Natural products COC1CC(=O)Oc2c(OC)c3occc3cc12 RNKZFOIQKCQOAQ-UHFFFAOYSA-N 0.000 claims description 2
- YXCORZFYRFZUOV-UHFFFAOYSA-N Xanthotoxol Natural products COc1c2OC(O)C=Cc2cc3ccoc13 YXCORZFYRFZUOV-UHFFFAOYSA-N 0.000 claims description 2
- 229960002045 bergapten Drugs 0.000 claims description 2
- KGZDKFWCIPZMRK-UHFFFAOYSA-N bergapten Natural products COC1C2=C(Cc3ccoc13)C=CC(=O)O2 KGZDKFWCIPZMRK-UHFFFAOYSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- DFMAXQKDIGCMTL-UHFFFAOYSA-N isopimpinellin Chemical compound O1C(=O)C=CC2=C1C(OC)=C1OC=CC1=C2OC DFMAXQKDIGCMTL-UHFFFAOYSA-N 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- JWVYQQGERKEAHW-UHFFFAOYSA-N xanthotoxol Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2O JWVYQQGERKEAHW-UHFFFAOYSA-N 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000003978 infusion fluid Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 241000700159 Rattus Species 0.000 abstract description 35
- 241000699670 Mus sp. Species 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 11
- 230000008961 swelling Effects 0.000 abstract description 8
- 229940117173 croton oil Drugs 0.000 abstract description 7
- 210000002919 epithelial cell Anatomy 0.000 abstract description 7
- 230000000392 somatic effect Effects 0.000 abstract description 7
- 235000014103 egg white Nutrition 0.000 abstract description 6
- 210000000969 egg white Anatomy 0.000 abstract description 6
- 208000024891 symptom Diseases 0.000 abstract description 6
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 5
- 208000003251 Pruritus Diseases 0.000 abstract description 5
- 208000026935 allergic disease Diseases 0.000 abstract description 5
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 abstract description 4
- 239000008187 granular material Substances 0.000 abstract description 4
- 230000009610 hypersensitivity Effects 0.000 abstract description 4
- 230000005764 inhibitory process Effects 0.000 abstract description 4
- 241000700199 Cavia porcellus Species 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 abstract description 3
- 206010014025 Ear swelling Diseases 0.000 abstract description 2
- 230000001139 anti-pruritic effect Effects 0.000 abstract description 2
- 229960001340 histamine Drugs 0.000 abstract description 2
- 241000257303 Hymenoptera Species 0.000 abstract 1
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- 230000002939 deleterious effect Effects 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 231100000915 pathological change Toxicity 0.000 abstract 1
- 230000036285 pathological change Effects 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
- 239000010452 phosphate Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 210000003371 toe Anatomy 0.000 description 15
- NUZWLKWWNNJHPT-UHFFFAOYSA-N anthralin Chemical compound C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O NUZWLKWWNNJHPT-UHFFFAOYSA-N 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 11
- 210000003491 skin Anatomy 0.000 description 11
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 10
- 241000283973 Oryctolagus cuniculus Species 0.000 description 10
- 239000000706 filtrate Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241000700198 Cavia Species 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 210000005069 ears Anatomy 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 238000000862 absorption spectrum Methods 0.000 description 4
- 229960001660 histamine phosphate Drugs 0.000 description 4
- ZHIBQGJKHVBLJJ-UHFFFAOYSA-N histamine phosphate Chemical compound OP(O)(O)=O.OP(O)(O)=O.NCCC1=CNC=N1 ZHIBQGJKHVBLJJ-UHFFFAOYSA-N 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 235000019084 Selinum monnieri Nutrition 0.000 description 3
- 244000296102 Selinum monnieri Species 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000032823 cell division Effects 0.000 description 3
- 230000001054 cortical effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 230000001823 pruritic effect Effects 0.000 description 3
- 210000001082 somatic cell Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 244000137852 Petrea volubilis Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 210000000270 basal cell Anatomy 0.000 description 2
- 239000003659 bee venom Substances 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000010339 dilation Effects 0.000 description 2
- 210000000883 ear external Anatomy 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 244000144993 groups of animals Species 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 150000003839 salts Chemical group 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 231100000643 Substance intoxication Toxicity 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical class [H]C([H])([H])C(*)=O 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- XJDFBLQCLSBCGQ-UHFFFAOYSA-N anthracene-1-carbaldehyde Chemical compound C1=CC=C2C=C3C(C=O)=CC=CC3=CC2=C1 XJDFBLQCLSBCGQ-UHFFFAOYSA-N 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007665 chronic toxicity Effects 0.000 description 1
- 231100000160 chronic toxicity Toxicity 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229960002311 dithranol Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940068517 fruit extracts Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229940125698 hormone suppressant Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- OLOOJGVNMBJLLR-UHFFFAOYSA-N imperatorin Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OCC=C(C)C OLOOJGVNMBJLLR-UHFFFAOYSA-N 0.000 description 1
- XKVWLLRDBHAWBL-UHFFFAOYSA-N imperatorin Natural products CC(=CCOc1c2OCCc2cc3C=CC(=O)Oc13)C XKVWLLRDBHAWBL-UHFFFAOYSA-N 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000000498 stratum granulosum Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/234—Cnidium (snowparsley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrane Compounds (AREA)
Abstract
Description
그룹 | 투여량(mg/kg) | 마우스 | 체세포분열의 인덱스 % |
전체 쿠마린 | 150 | 15 | 11.3±2.0* |
전체 쿠마린 | 75 | 15 | 19.8±2.8** |
안트랄린 | 15 | 15 | 13.4±2.1* |
생리 식염 | 15ml | 15 | 22.2±2.4 |
그룹 | 투여량(g/래트) | 래트 | 과립층세포를 가진 비늘의 수(%, x±SD) |
쿠마린 연고 | 0.3 | 10 | 25.36±9.28* |
쿠마린 연고 | 0.3 | 10 | 18.45±8.78** |
안트랄린 연고*** | 0.3 | 10 | 21.76±8.51* |
블랭크 연고 | 0.3 | 10 | 10.87±5.64 |
그룹 | 투여량(mg/kg) | 동물 | OD | 억제(%) |
전체 쿠마린 | 150 | 15 | 0.029±0.018* | 67.42 |
전체 쿠마린 | 75 | 15 | 0.045±0.027** | 49.44 |
안트랄린 | 15 | 15 | 0.043±0.25* | 51.69 |
생리 식염 | 15ml | 15 | 0.089±0.41 |
그룹 | 투여량(g/귀) | 동물 | 귀 사이의 차이(mg) |
쿠마린 연고 | 0.3 | 20 | 1.52±0.76* |
쿠마린 연고 | 0.15 | 20 | 0.93±0.68** |
안트랄린 연고 | 0.3 | 20 | 0.95±0.71** |
블랭크 연고 | 0.3 | 20 | 0.49±0.25 |
그룹 | 투여량 (g/귀) |
동물 | 귀 팽창 정도(ml) | |||
1시간째 | 2시간째 | 4시간째 | 6시간째 | |||
쿠마린 연고 | 0.15 | 10 | 0.401±0.210* | 0.386±0.183* | 0.371±0.167* | 0.354±0.152* |
쿠마린 연고 | 0.3 | 10 | 0.324±0.181** | 0.308±0.168** | 0.290±0.146** | 0.290±0.146** |
안트랄린 | 0.3 | 10 | 0.408±0.201* | 0.391±0.209* | 0.375±0.189** | 0.351±0.165* |
블랭크 연고 | 0.3 | 10 | 0.584±0.205 | 0.579±0.198 | 0.554±0.186 | 0.528±0.181 |
대조군 | 10 | 0.612±0.207 | 0.608±0.214 | 0.591±0.195 | 0.486±0.104 |
그룹 | 투여량(g/발가락) | 동물 | 소양 역치(ug) |
쿠마린 연고 | 0.15 | 10 | 142.75±120.15* |
쿠마린 연고 | 0.3 | 10 | 206.25±111.60** |
안트랄린 연고 | 0.3 | 10 | 158.50±131.48* |
블랭크 연고 | 0.3 | 10 | 38.75±20.14 |
대조군 | 10 | 37.50±25.00 |
그룹 | 환자 | 치유적 | 효과적 | 효과적 | 비효과적 | 매우 효과적 |
쿠마린 연고 | 30 | 18 | 9 | 2 | 1 | 96.7% |
안트랄린 연고 | 30 | 12 | 16 | 2 | 0 | 100% |
Claims (5)
- 유효성분으로서 벌사상자 열매의 추출물, 및 제약학적으로 허용가능한 담체 또는 부형제 또는 이들 모두를 포함하며,
상기 추출물은 85 중량% 이상의 쿠마린 화합물을 포함하고, 이 중 오스탈(osthal)이 90 중량% 이상을 차지하며,
상기 추출물이 벌사상자 열매를 60-80℃에서 80-95% 에탄올과 접촉시킴에 의하여 제조된 것을 특징으로 하는 건선 치료용 약제. - 제1항에 있어서,
상기 접촉을 2 시간 동안 수행함을 특징으로 하는 약제. - 제1항에 있어서,
상기 벌사상자 열매가 분말의 형태임을 특징으로 하는 약제. - 제1항에 있어서,
상기 약제가 연고, 정제 또는 주입용액으로서 제형화됨을 특징으로 하는 약제. - 제1항에 있어서,
상기 쿠마린 화합물이 크산토톡솔(xanthotoxol), 크산토톡신(xanthotoxin), 이소핌피넬린(isopimpinellin), 베르갑텐(bergapten) 및 임페라토린(imperatorine)을 포함함을 특징으로 하는 약제.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB021149038A CN1197867C (zh) | 2002-02-27 | 2002-02-27 | 蛇床子总香豆素在制备治疗银屑病药物中的应用 |
CN02114903.8 | 2002-02-27 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020047013365A Division KR101016680B1 (ko) | 2002-02-27 | 2003-02-26 | 건선 치료용 약제 제조를 위한 벌사상자 열매의 전체 쿠마린의 용도 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20100099352A true KR20100099352A (ko) | 2010-09-10 |
KR101207479B1 KR101207479B1 (ko) | 2012-12-03 |
Family
ID=4743351
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020107018912A KR101207479B1 (ko) | 2002-02-27 | 2003-02-26 | 건선 치료용 약제 제조를 위한 벌사상자 열매의 전체 쿠마린의 용도 |
KR1020047013365A KR101016680B1 (ko) | 2002-02-27 | 2003-02-26 | 건선 치료용 약제 제조를 위한 벌사상자 열매의 전체 쿠마린의 용도 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020047013365A KR101016680B1 (ko) | 2002-02-27 | 2003-02-26 | 건선 치료용 약제 제조를 위한 벌사상자 열매의 전체 쿠마린의 용도 |
Country Status (11)
Country | Link |
---|---|
US (3) | US8124133B2 (ko) |
EP (1) | EP1486213B1 (ko) |
JP (1) | JP4613012B2 (ko) |
KR (2) | KR101207479B1 (ko) |
CN (2) | CN1197867C (ko) |
AT (1) | ATE541579T1 (ko) |
AU (1) | AU2003221280B2 (ko) |
CA (1) | CA2477019C (ko) |
DK (1) | DK1486213T3 (ko) |
RU (1) | RU2311188C2 (ko) |
WO (1) | WO2003072120A1 (ko) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6596125B2 (en) | 2001-09-21 | 2003-07-22 | Philip Morris Incorporated | Method and apparatus for applying a material to a web |
CN1197867C (zh) * | 2002-02-27 | 2005-04-20 | 杨利平 | 蛇床子总香豆素在制备治疗银屑病药物中的应用 |
CN100542527C (zh) * | 2003-10-17 | 2009-09-23 | 株式会社Lg生活健康 | 促进胶原合成的组合物和包含它的皮肤外用制剂组合物 |
CN100404524C (zh) * | 2005-07-22 | 2008-07-23 | 中国医学科学院放射医学研究所 | 高纯度蛇床子素及其制备方法和以该化合物为活性成分的药物组合物 |
JP2009137889A (ja) * | 2007-12-06 | 2009-06-25 | Lion Corp | 育毛養毛剤、育毛養毛用組成物および育毛養毛方法 |
KR101698830B1 (ko) * | 2015-04-08 | 2017-01-23 | 주식회사 오비엠랩 | 피지 과다분비 또는 지루성 피부염의 억제 또는 개선용 조성물 |
KR20190046241A (ko) | 2017-10-25 | 2019-05-07 | (주)예스킨 | 건선 개선 식품조성물 |
CN108030903A (zh) * | 2017-12-14 | 2018-05-15 | 珠海横琴新区德群中医药科学研究院有限公司 | 一种用于治疗牛皮癣的中药 |
RU2743848C1 (ru) * | 2020-06-25 | 2021-02-26 | Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) | Способ коррекции гиперкоагуляционного состояния при введении противоопухолевого препарата цисплатина |
CN111728968A (zh) * | 2020-07-08 | 2020-10-02 | 桂林医学院 | 瑞香素在制备治疗银屑病的药物中的应用 |
CN112426413A (zh) * | 2020-11-13 | 2021-03-02 | 川北医学院附属医院 | 一种花椒毒酚水溶性纳米新剂型的制备方法及应用 |
CN115969891A (zh) * | 2022-10-13 | 2023-04-18 | 杨利平 | 一种蛇床子总提取物及其应用和图谱构建方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5953476A (ja) | 1982-09-20 | 1984-03-28 | Res Inst For Prod Dev | クマリン誘導体 |
JPS5953477A (ja) | 1982-09-20 | 1984-03-28 | Res Inst For Prod Dev | クマリン誘導体 |
JPH01235036A (ja) * | 1988-03-15 | 1989-09-20 | Sony Corp | 光学ピックアップ装置 |
JPH0459733A (ja) * | 1990-06-29 | 1992-02-26 | Ota Isan:Kk | 蛇床子抽出・精製物を有効成分とするストレスによる機能障害改善剤 |
KR0148511B1 (ko) * | 1993-09-14 | 1998-11-02 | 최형기 | 성신경과민증 예방 및 치료용 의약조성물 |
CN1102993A (zh) * | 1993-12-21 | 1995-05-31 | 吴文才 | 多酶体系加工中草药的制剂方法 |
JP3577110B2 (ja) * | 1994-08-29 | 2004-10-13 | 株式会社ヤクルト本社 | Acat阻害剤 |
US5961997A (en) * | 1997-03-25 | 1999-10-05 | Swinehart; James M. | Antipruritic composition |
JP2002255812A (ja) * | 2001-03-02 | 2002-09-11 | Dai Ichi Seiyaku Co Ltd | 抗掻痒剤 |
CN1197867C (zh) * | 2002-02-27 | 2005-04-20 | 杨利平 | 蛇床子总香豆素在制备治疗银屑病药物中的应用 |
-
2002
- 2002-02-27 CN CNB021149038A patent/CN1197867C/zh not_active Expired - Lifetime
- 2002-02-27 CN CNB2004100792505A patent/CN1327837C/zh not_active Expired - Lifetime
-
2003
- 2003-02-26 KR KR1020107018912A patent/KR101207479B1/ko active IP Right Grant
- 2003-02-26 AU AU2003221280A patent/AU2003221280B2/en not_active Ceased
- 2003-02-26 JP JP2003570865A patent/JP4613012B2/ja not_active Expired - Fee Related
- 2003-02-26 KR KR1020047013365A patent/KR101016680B1/ko active IP Right Grant
- 2003-02-26 CA CA002477019A patent/CA2477019C/en not_active Expired - Lifetime
- 2003-02-26 RU RU2004128461/15A patent/RU2311188C2/ru active
- 2003-02-26 AT AT03709569T patent/ATE541579T1/de active
- 2003-02-26 EP EP03709569A patent/EP1486213B1/en not_active Expired - Lifetime
- 2003-02-26 DK DK03709569.2T patent/DK1486213T3/da active
- 2003-02-26 US US10/505,015 patent/US8124133B2/en active Active
- 2003-02-26 WO PCT/CN2003/000150 patent/WO2003072120A1/zh active IP Right Grant
-
2012
- 2012-01-21 US US13/355,532 patent/US8518460B2/en active Active
-
2013
- 2013-08-01 US US13/956,378 patent/US10383843B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
DK1486213T3 (da) | 2012-05-14 |
EP1486213A4 (en) | 2006-04-26 |
US10383843B2 (en) | 2019-08-20 |
US20050123636A1 (en) | 2005-06-09 |
US8124133B2 (en) | 2012-02-28 |
EP1486213A1 (en) | 2004-12-15 |
CA2477019A1 (en) | 2003-09-04 |
JP2005530697A (ja) | 2005-10-13 |
EP1486213B1 (en) | 2012-01-18 |
US8518460B2 (en) | 2013-08-27 |
AU2003221280B2 (en) | 2007-06-28 |
CN1374309A (zh) | 2002-10-16 |
RU2004128461A (ru) | 2005-03-27 |
WO2003072120A1 (fr) | 2003-09-04 |
ATE541579T1 (de) | 2012-02-15 |
KR101016680B1 (ko) | 2011-02-25 |
RU2311188C2 (ru) | 2007-11-27 |
KR101207479B1 (ko) | 2012-12-03 |
CN1701791A (zh) | 2005-11-30 |
JP4613012B2 (ja) | 2011-01-12 |
AU2003221280A1 (en) | 2003-09-09 |
CN1197867C (zh) | 2005-04-20 |
CN1327837C (zh) | 2007-07-25 |
KR20040083461A (ko) | 2004-10-01 |
US20120115940A1 (en) | 2012-05-10 |
CA2477019C (en) | 2009-10-27 |
US20150038568A1 (en) | 2015-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10383843B2 (en) | Use of total coumarins of cnidium fruit in preparing medicaments for treating psoriasis | |
KR101445010B1 (ko) | 소염, 부기제거, 진통에 사용되는 중국 생약 조성물, 그 제조 방법 및 용도 | |
EP0279984B1 (en) | Pharmaceutical use of graminaceous extracts | |
CN109700720B (zh) | 一种婴儿护理膏及其制备方法 | |
KR20120027432A (ko) | 밤껍질 추출물을 포함하는 건강 식품 또는 약학 조성물 | |
WO2012012390A1 (en) | Botanical composition and methods of manufacture and use | |
KR20030055154A (ko) | 피부질환 치료용 조성물 및 그 제조방법 | |
US9364510B2 (en) | Botanical composition and methods of manufacture and use | |
CN114010700A (zh) | 一种含有中药有效成分的无创真皮渗透技术透皮吸收剂的制备方法与应用 | |
CN107412455A (zh) | 一种治疗皮疹的天然外用药物组合物及其制备方法 | |
WO2013154806A1 (en) | Herbal composition and a method of making thereof | |
TWI815349B (zh) | 山竹果殼萃取物用於製備促進糖尿病傷口癒合的藥物的用途 | |
Gavale et al. | HERBAL DRUGS USE IN A SKIN DISORDERS REVIEW ARTICLE | |
CN114668809B (zh) | 一种用于改善整形美容副作用的药物 | |
CN116036105A (zh) | 一种治疗淋巴水肿的药物运用 | |
CN116036106A (zh) | 一种治疗淋巴水肿的药物运用 | |
CN105920103A (zh) | 一种治疗脚气的外用喷剂及其制备方法 | |
EP1131101A1 (de) | Khellin-zubereitung und deren verwendung zur topischen therapie | |
CN105534998A (zh) | 一种治疗皮肤干燥引起的皮肤瘙痒的外用制剂及其制备方法 | |
KR20240032428A (ko) | 무화과 추출물을 포함하는 건선의 예방 및 치료용 조성물 | |
CN105477272B (zh) | 一种海洋生物护伤喷膜剂 | |
CN114099493A (zh) | 一种抑制胰岛素抵抗的活性化合物及其应用 | |
CN112107632A (zh) | 一种祛湿毒瘀的外用药物组合物及制备方法 | |
CN115282194A (zh) | 一种用于清热除湿、杀虫止痒的中药组合物的制备方法 | |
CN115282205A (zh) | 一种妇炎清洗剂中药组合物的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A107 | Divisional application of patent | ||
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application | ||
J201 | Request for trial against refusal decision | ||
J501 | Disposition of invalidation of trial | ||
J301 | Trial decision |
Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20110729 Effective date: 20120822 |
|
S901 | Examination by remand of revocation | ||
GRNO | Decision to grant (after opposition) | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20151124 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20161021 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20171012 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20181010 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20191014 Year of fee payment: 8 |